PatientSpotlight, by PanaceaIntelPatientSpotlight

Snapshots · Women's Health · 7 pieces

Snapshots

The landscape laid out as it stands today - therapies, diagnostic pathways, regulatory and reimbursement positions. Snapshots are reference pages, not arguments.

FilterAll (64)Oncology (6)Rare Disease (7)Immunology (6)Neurology (15)Cardiometabolic (6)Respiratory (5)Women's Health (7)Mental Health (6)Ophthalmology (6)
Each Snapshot is dated and refreshed when material changes occur. They are written for people who need the field laid out at a glance - not the latest move in it.

Treatment

4
SnapshotNEWMay 8, 2026

Nausea and vomiting in pregnancy therapy reference (2026)

Reference snapshot of nausea and vomiting in pregnancy therapy from mild morning sickness through hyperemesis gravidarum.

TreatmentPatient journeyInfrastructure
SnapshotNEWMay 7, 2026

Overactive bladder therapy reference (2026)

Reference snapshot of overactive bladder therapy across behavioural, pharmacological, and procedural tiers.

TreatmentPatient journeyDelivery
SnapshotNEWMay 5, 2026

Vasomotor symptom therapy reference (2026)

Reference snapshot of vasomotor symptom therapy across hormone, non-hormonal pharmacotherapy, and emerging mechanism-targeted tiers.

TreatmentPatient journeyAccess
SnapshotNEWMay 4, 2026

Postmenopausal osteoporosis therapy reference (2026)

Reference snapshot of postmenopausal osteoporosis therapy across anti-resorptive and anabolic tiers.

TreatmentPatient journeyDiagnosis

Pipeline

2
SnapshotApr 26, 2026FDA · industry-filing

Maternal mental health pipeline, 2026 mid-year reference

Reference layout of the maternal mental health pipeline as of mid-2026: approved mechanisms for postpartum depression, late-stage assets for perinatal mood disorders and adjacent indications, and the live commercial questions including screening pathway and access frame.

PipelineTreatment
SnapshotApr 26, 2026clinical-trial · industry-filing

Endometriosis pipeline, 2026 mid-year reference

Reference layout of the endometriosis pipeline as of mid-2026: approved mechanisms, late-stage assets, the GnRH antagonist class, the non-hormonal pipeline, and the live commercial questions including diagnosis-pathway access and the surgical-medical interplay.

PipelineTreatment

Other

1
SnapshotApr 30, 2026

Menopause therapy options (2026 reference)

Reference snapshot of approved and emerging menopause therapy options.